Business Context and Reporting Period
This Form 8-K Current Report was filed by Atara Biotherapeutics, Inc. on December 9, 2015. The filing discloses the entry into a material definitive agreement regarding new corporate office space.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on the terms of a new lease agreement.
- Lease Size: 13,670 rentable square feet.
- Location: 611 Gateway Boulevard, Suite 900, South San Francisco, California.
- Lease Term: Five years and one month, commencing February 1, 2016.
- Base Rent Schedule (per sq. ft.): $3.35 (Year 1), $3.45 (Year 2), $3.55 (Year 3), $3.66 (Year 4), $3.77 (Year 5), and $3.88 (Final Month).
- Additional Costs: The Company is responsible for specified percentages of operating expenses, property management fees, and taxes.
Material Changes
The material change reported is the execution of a new five-year office lease with BXP 611 Gateway Center LP. This represents a new long-term operating commitment for the Company.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. The primary contingency noted is the obligation to pay variable operating expenses and taxes in addition to the fixed base rent. The full text of the Lease agreement is referenced as an exhibit to the upcoming Form 10-K.
Investor Verification Checklist
- Verify the total annualized cost of the lease including estimated operating expenses and taxes.
- Confirm the impact of this new fixed cost on the Company's cash burn rate.
- Review the full Lease agreement in the subsequent Form 10-K for termination clauses or renewal options.
- Assess whether the 13,670 square feet aligns with current and projected headcount needs.